Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Epilepsy ll: Types01:22

Epilepsy ll: Types

Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retraction notice to "A level of trust: Exploring entrustable professional activities as a feedback tool in a skills lab" [Currents in Pharmacy Teaching and Learning 15 (2023) 1034-1039].

Currents in pharmacy teaching & learning·2026
Same author

The Relationship Between Nursing Quality and Patient Experience in Acute Care Settings.

Journal of patient safety·2026
Same author

Identification of risk factors for impostor phenomenon among healthcare professional students.

Currents in pharmacy teaching & learning·2025
Same author

Tiered Training and Licensure for the Future of the Pharmacy Profession: Panacea or Pandora's Box?

American journal of pharmaceutical education·2025
Same author

Blending Early Warning and Remediation Processes to Facilitate Student Success.

American journal of pharmaceutical education·2025
Same author

A level of trust: Exploring entrustable professional activities as a feedback tool in a skills lab.

Currents in pharmacy teaching & learning·2024

Related Experiment Video

Updated: Jun 8, 2026

Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients
09:32

Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients

Published on: December 18, 2016

Lacosamide and epilepsy.

Jacklyn A Harris1, Julie A Murphy

  • 1Department of Pharmacy Practice, St. Louis College of Pharmacy, St. Louis, MO 63110-1088, USA. jharris2@stlcop.edu

CNS Neuroscience & Therapeutics
|October 19, 2010
PubMed
Summary

Lacosamide effectively reduces partial-onset seizure frequency when used as an add-on treatment. This antiepileptic drug demonstrates a favorable safety profile with mild side effects in patients with refractory epilepsy.

Area of Science:

  • Neurology
  • Pharmacology
  • Clinical Trials

Background:

  • Partial-onset seizures are a common form of epilepsy.
  • Refractory epilepsy poses significant treatment challenges.
  • Identifying effective adjunctive therapies is crucial for improving patient outcomes.

Purpose of the Study:

  • To systematically review the available evidence on the safety and efficacy of lacosamide for partial-onset seizures.
  • To evaluate both oral and intravenous formulations of lacosamide.
  • To assess lacosamide's role as an adjunctive treatment in refractory cases.

Main Methods:

  • Review of open-label studies and randomized controlled trials.
  • Analysis of data on seizure frequency reduction.
  • Evaluation of adverse drug effects and tolerability.

More Related Videos

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Preparation of Acute Human Hippocampal Slices for Electrophysiological Recordings
07:31

Preparation of Acute Human Hippocampal Slices for Electrophysiological Recordings

Published on: May 7, 2020

Related Experiment Videos

Last Updated: Jun 8, 2026

Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients
09:32

Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients

Published on: December 18, 2016

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Preparation of Acute Human Hippocampal Slices for Electrophysiological Recordings
07:31

Preparation of Acute Human Hippocampal Slices for Electrophysiological Recordings

Published on: May 7, 2020

Main Results:

  • Lacosamide (400-600 mg daily) significantly reduced seizure frequency.
  • Oral and intravenous lacosamide showed favorable safety and tolerability.
  • Adverse effects were generally mild and infrequently reported.

Conclusions:

  • Lacosamide is an efficacious adjunctive treatment for refractory partial-onset seizures.
  • The drug presents a favorable benefit-risk profile.
  • Further research may explore long-term outcomes and specific patient populations.